This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Burzynski, S. R. Articles by Szymkowski, B. Search for Related Content PubMed PubMed Citation Articles by Burzynski, S. R. Articles by Szymkowski, B. Social Bookmarking                         What's this?

Long-Term Survival and Complete Response of a Patient with Recurrent Diffuse Intrinsic Brain Stem Glioblastoma Multiforme

Department of Internal Medicine, Burzynski Clinic, Houston, Texas, info{at}burzynskiclinic.com

Robert I. Lewy, MD, FACP

Department of Medical Oncology, Burzynski Clinic, Houston, Texas

Robert Weaver, MD

Department of Internal Medicine, Burzynski Clinic, Houston, Texas

Tomasz Janicki, MD

Department of Medical Documentation/Data Processing, Burzynski Clinic, Houston, Texas

Gabor Jurida, MD

Department of Internal Medicine, Burzynski Clinic, Houston, Texas

Mohammad Khan, MD

Department of Radiology, Burzynski Clinic, Houston, Texas

Chymbeelyn B. Larisma, MD

Department of Medical Oncology, Burzynski Clinic, Houston, Texas

Jaroslaw Paszkowiak, MD

Department of Quality Assurance, Burzynski Research Institute, Houston, Texas

Barbara Szymkowski, MD

Department of Internal Medicine, Burzynski Clinic, Houston, Texas

Recurrent diffuse intrinsic brain stem glioblastoma multiforme carries an extremely poor prognosis and a median survival of less than 7 months. In this article, the authors report good results in a 40-year-old man diagnosed with glioblastoma multiforme who received antineoplastons. The patient’s brain tumor was diagnosed in May 1999, and he subsequently underwent subtotal tumor resection and standard radiation therapy. Magnetic resonance imaging and positron emission tomography scans documented his tumor recurrence. Approximately 2 months after completion of radiation therapy, he was admitted for administration of intravenous antineoplastons A10 and AS2-1 through a subclavian venous catheter by intermittent bolus injections 6 times per day using a portable pump. Administration of antineoplastons A10 and AS2-1 was over 655 consecutive days with the exception of a few short interruptions. The maximum dosage of A10 was 8.15 g/kg/d and AS2-1 0.35 g/kg/d. Antineoplastons A10 and AS2-1 administration was very well tolerated with only mild reversible side effects. Follow-up magnetic resonance imaging and positron emission tomography scans revealed decrease and eventually disappearance of the tumor. A complete response was documented after approximately 1 year of antineoplastons A10 and AS2-1 administration. More than 4 years later, off antineoplastons A10 and AS2-1, the patient is tumor free, able to carry on normal activities, and works full-time, and his Karnofsky Performance Status increased from 50 to 100. Extensive phase II trials with antineoplastons A10 and AS2-1 in patients with glioblastoma multiforme are nearing completion. These trials may provide more data regarding the efficacy of antineoplastons A10 and AS2-1 in the treatment of glioblastoma multiforme in untreated patients compared to the results in those patients with tumor recurrence after radiation therapy.

Key Words: brain stem glioma • GBM • brain tumor • glioma • antineoplastons • phenylacetate • phenylbutyrate

Integrative Cancer Therapies, Vol. 3, No. 3, 257-261 (2004)
DOI: 10.1177/1534735404267748


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. R. Burzynski, T. J. Janicki, R. A. Weaver, and B. Burzynski Targeted Therapy With Antineoplastons A10 and AS2-1 of High-Grade, Recurrent, and Progressive Brainstem Glioma Integr Cancer Ther, March 1, 2006; 5(1): 40 - 47. [Abstract] [PDF]

				S. R. Burzynski, R. A. Weaver, T. Janicki, B. Szymkowski, G. Jurida, M. Khan, and V. Dolgopolov Long-term Survival of High-Risk Pediatric Patients With Primitive Neuroectodermal Tumors Treated With Antineoplastons A10 and AS2-1 Integr Cancer Ther, June 1, 2005; 4(2): 168 - 177. [Abstract] [PDF]